CBEYOND

CBEYOND
Recruiting
18 years - 85 years
All
Phase 3
1 Location

Brief description of study

Phase 3, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvir-Ruzasvir Fixed-dose Combination (BEM/RZR FDC) Versus Sofosbuvir-Velpatasvir Fixed-dose Combination (SOF/VEL FDC) in Subjects with Chronic Hepatitis C Virus (HCV) Infection

Detailed description of study

Penn researchers are looking for people who may be interested in taking part in the C-BEYOND clinical research study. The purpose of this study is to compare the safety and effectiveness of an investigational drug (study drug) with a comparator drug. The comparator drug is a generic version of a drug approved in the United States and Canada to treat HCV, but this generic version being used in the study has only been authorized in the United States. You may be eligible to participate in this HCV infection study if you:
•    are 18–85 years of age,
•    have a chronic HCV infection, and
•    do not have a hepatitis B virus infection.
 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 18 years - 85 years
  • Gender: All

Documented HCV, No prior use of direct-acting antiviral (DAA) treatment

Updated on 02 Apr 2026. Study ID: 25-1103

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team


Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center